460 related articles for article (PubMed ID: 16623782)
1. Uterine leiomyoma versus leiomyosarcoma: a new attempt at differential diagnosis based on their cellular characteristics.
Watanabe K; Suzuki T
Histopathology; 2006 Apr; 48(5):563-8. PubMed ID: 16623782
[TBL] [Abstract][Full Text] [Related]
2. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
Petrović D; Babić D; Forko JI; Martinac I
Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
[TBL] [Abstract][Full Text] [Related]
3. Uterine leiomyosarcoma arising in leiomyoma: clinicopathological study of four cases and literature review.
Yanai H; Wani Y; Notohara K; Takada S; Yoshino T
Pathol Int; 2010 Jul; 60(7):506-9. PubMed ID: 20594271
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of biological potential of smooth muscle tumours.
Miettinen M; Fetsch JF
Histopathology; 2006 Jan; 48(1):97-105. PubMed ID: 16359541
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
6. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants.
Gannon BR; Manduch M; Childs TJ
Int J Gynecol Pathol; 2008 Jan; 27(1):68-73. PubMed ID: 18156978
[TBL] [Abstract][Full Text] [Related]
7. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
8. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Fertil Steril; 2004 Apr; 81(4):1062-6. PubMed ID: 15066464
[TBL] [Abstract][Full Text] [Related]
9. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
[TBL] [Abstract][Full Text] [Related]
10. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
11. The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
Atkins KA; Arronte N; Darus CJ; Rice LW
Am J Surg Pathol; 2008 Jan; 32(1):98-102. PubMed ID: 18162776
[TBL] [Abstract][Full Text] [Related]
12. Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma.
Zhang P; Zhang C; Hao J; Sung CJ; Quddus MR; Steinhoff MM; Lawrence WD
Hum Pathol; 2006 Oct; 37(10):1350-6. PubMed ID: 16949924
[TBL] [Abstract][Full Text] [Related]
13. Fascin expression in uterine smooth muscle tumors.
Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
[TBL] [Abstract][Full Text] [Related]
14. Smooth muscle tumours of the uterine corpus: a clinicopathologic study with immunohistochemical aspects.
Waldmann J; Stachs A; Terpe H; Stropahl G; Makovitzky J
Anticancer Res; 2005; 25(3A):1559-65. PubMed ID: 16033061
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas.
Poncelet C; Fauvet R; Feldmann G; Walker F; Madelenat P; Darai E
J Surg Oncol; 2004 May; 86(2):84-90. PubMed ID: 15112250
[TBL] [Abstract][Full Text] [Related]
16. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases.
Chu PG; Arber DA; Weiss LM; Chang KL
Mod Pathol; 2001 May; 14(5):465-71. PubMed ID: 11353058
[TBL] [Abstract][Full Text] [Related]
17. Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas.
Mittal K; Joutovsky A
Gynecol Oncol; 2007 Feb; 104(2):362-5. PubMed ID: 17011615
[TBL] [Abstract][Full Text] [Related]
18. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
19. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
